All In Biotech

Drug Trial Radar · NCT00566527

Comparative Study of Immunogenicity and Safety of a 2-dose Regimen of ProQuad® Manufactured With rHA (V221-038)

An Open-label, Randomised, Comparative, Multi-centre Study of the Immunogenicity and Safety of a 2-dose Regimen of ProQuad® Manufactured With rHA Administered to Healthy Children From 9 Months of Age

Last checked: Nov 20, 2026Latest source record: Jan 30, 2018 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 1,620 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

1,620

Actual

Start

Nov 29, 2007

Primary completion

Dec 29, 2008

Study completion Dec 29, 2008

Sponsor

Lead sponsor
Merck Sharp & Dohme LLCMerck & Co. (MRK)
Sponsor type
Industry
First posted
Dec 3, 2007

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Prevention
FDA-regulated drug
Yes
Who can join
All sexes, from 9 months
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

The primary study objectives are: * To demonstrate that a 2-dose regimen of ProQuad® manufactured with recombinant Human Albumin (rHA) administered at a 3-month interval to healthy children of 11 months of age at the time of Dose 1 is as immunogenic as in healthy children of 12 months of age at the time of Dose 1. * To demonstrate that a 2-dose regimen of ProQuad® rHA administered at a 3-month interval to healthy children of 9 months of age at the time of Dose 1 is as immunogenic as in healthy children of 12 months of age at the time of Dose 1. * To demonstrate that a 2-dose regimen of ProQuad® rHA administered at a 3-month interval to healthy children of 11 months of age and 9 months of age at the time of Dose 1 is well-tolerated compared to children of 12 months of age at the time of Dose 1. The first primary hypothesis was that a 2-dose regimen of ProQuad® rHA, administered at a 3-month interval to children of 11 months of age, would be non-inferior in terms of antibody response rates to measles, mumps, rubella, and varicella at Day 42 following Dose 2, to the same regimen in children of 12 months of age at the time of Dose 1. If the first primary hypothesis was demonstrated, the second primary hypothesis was that a 2-dose regimen of ProQuad® rHA, administered at a 3-month interval to children of 9 months of age, would be non-inferior in terms of antibody response rates to measles, mumps, rubella, and varicella at Day 42 following Dose 2, to the same regimen in children of 12 months of age at the time of Dose 1. The secondary study objectives are: * To describe the antibody titres to measles, mumps, rubella and varicella at Day 42 following Dose 1 and Dose 2 of ProQuad® rHA administered to healthy children from 9 months of age. * To evaluate the safety profile of Dose 1 and Dose 2 of ProQuad® rHA administered to healthy children from 9 months of age.

Conditions

  • Measles
  • Mumps
  • Rubella
  • Varicella

Interventions

  • ProQuad® manufactured with recombinant Human Albumin (rHA)Biological

    A 2-dose regimen of ProQuad® (0.5 mL per dose) given via subcutaneous injection into the deltoid muscle at a 3-month interval. Each dose contains measles virus Enders' Edmonston strain (live attenuated), mumps virus Jeryl Lynn™ (Level B) strain (live attenuated), rubella virus Wistar RA 27 or 3 strain (live attenuated), and varicella virus Oka or Merck strain (live attenuated).

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Percentage of Participants in Arm 2 and Arm 3 Meeting Antibody Immunogenicity Response Criteria Following ProQuad® Dose 2Time frame: Day 132 (6 weeks after ProQuad® Dose 2)
  2. Percentage of Participants in Arm 1 and Arm 3 Meeting Antibody Immunogenicity Response Criteria Following ProQuad® Dose 2Time frame: Day 132 (6 weeks after ProQuad® Dose 2)
  3. Percentage of Participants With Solicited Injection-site Adverse ReactionsTime frame: Day 1 to Day 4 (up to 4 days after ProQuad® Dose 1)
  4. Percentage of Participants Experiencing Unsolicited Injection-site Adverse ReactionsTime frame: Up to Day 28 (up to 28 days after ProQuad® Dose 1)
  5. Percentage of Participants Experiencing a Systemic Adverse Event After ProQuad® Dose 1Time frame: Up to Day 28 (up to 28 days after ProQuad® Dose 1)
  6. Percentage of Participants With Rectal (or Rectal Equivalent) Temperature ≥ 39.4°CTime frame: Up to Day 28 (up to 28 days after ProQuad® Dose 1)

Locations

No sites are listed on the registry yet.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.